Ordastobart
Ordastobart (INBRX-106; ES-102) is a hexavalent OX40 agonist antibody. Ordastobart enhances OX40 receptor clustering, signaling, and downstream activation, thereby increasing the proliferation and activation of CD4+ and CD8+ T cells in vitro and in vivo. Ordastobart exhibits anti-tumor effects and improves survival in mouse models of cancer. Ordastobart is indicated for research in cancers such as fibrosarcoma and colorectal cancer[1].
Product Specifications
CAS Number
[2708115-83-5]
Product Name Alternative
INBRX-106; ES-102
UNSPSC
12352203
Target
Orexin Receptor (OX Receptor)
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Purity
98
Smiles
[Ordastobart]
References & Citations
[1]Rowell E, et al. 856 INBRX-106: a novel hexavalent anti-OX40 agonist for the treatment of solid tumors[J]. Journal for ImmunoTherapy of Cancer, 2021, 9 (Suppl 2) : A897-A897.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
